Tenaya Therapeutics (TNYA) Current Leases (2021 - 2026)

Tenaya Therapeutics' Current Leases history runs 6 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• On a quarterly basis, Current Leases rose 11.49% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 11.49% increase from a year earlier, with the FY2025 full-year figure at $3.0 million, up 8.71% from the prior year.
• Current Leases improved to $3.1 million in Q1 2026 per TNYA's latest filing, from $3.0 million in the prior quarter.
• Across five years, Current Leases topped out at $4.3 million in Q4 2023 and bottomed at $2.1 million in Q1 2022.
• The 5-year median for Current Leases is $3.2 million (2023), against an average of $3.3 million.
• Across the five-year window, Current Leases soared 138.0% in 2022 and slumped 35.68% in 2024, its largest moves.
• Year by year, Current Leases stood at $4.0 million in 2022, then grew by 7.81% to $4.3 million in 2023, then plunged by 35.68% to $2.8 million in 2024, then climbed by 8.71% to $3.0 million in 2025, then climbed by 3.15% to $3.1 million in 2026.
• Per Business Quant, the three latest TNYA Current Leases figures stand at $3.1 million (Q1 2026), $3.0 million (Q4 2025), and $2.9 million (Q3 2025).